Reported results
- Total PreTRM test revenue was $42,000 for the third quarter of 2026.
- GAAP net loss was $8,053,000 for the third quarter of 2026.
- GAAP operating expenses were $8,929,000 for the third quarter of 2026.
- GAAP net loss per share, basic and diluted, was $0.16 for the third quarter of 2026.
- Cash, cash equivalents and marketable investment securities totaled $72.8 million at the end of the third quarter of 2026.
Notes
The company reported approximately $0.4 million in severance related expenses in the third quarter tied to restructuring.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-04 (8-K, Item 2.02). Read the original filing on sec.gov.
